Posted by Michael Wonder on 15 Oct 2020
NICE recommends Novartis’ Mayzent on the heels of SMC approval
15 October 2020 - NICE has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium approved the multiple sclerosis drug.
Mayzent (siponimod) is licensed to delay disability progression and cognitive decline in secondary progressive multiple sclerosis with active disease.
Following the NICE and SMC recommendations, Mayzent becomes the first oral disease-modifying therapy approved for adult patients with SPMS in England, Wales and Scotland.
